Vanda licenses iloperidone from Novartis; Rights returned
Executive Summary
Vanda Pharmaceuticals (genomics tools for drug discovery) has sublicensed worldwide rights from Novartis Pharma AG to develop and sell Titan Pharmaceuticals' iloperidone for schizophrenia and related psychotic disorders.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice